ORION CORPORATION
INVESTOR NEWS
25 MAY 2023 at 10.30 EEST
Orion hosts its Capital Markets Day today, May 25, 2023, in Helsinki
Orion hosts its Capital Markets Day for analysts, institutional investors and other capital market representatives, and media representatives in Helsinki today, May 25, 2023. During the event, company's management will introduce Orion's new business divisions and provide an update on Orion's R&D and drivers for growth and profitability. Orion will not publish new strategic or financial targets in connection to the event.
The presentation material is now published on Orion's website https://www.orion.fi/en/cmd2023. The presentations include, among other things, the following information, which is of interest to investors, but is not considered to be material information about the company.
- A new molecule, ODM-212, is about to enter clinical phase I trial in H2 2023.
- Easyhaler® product portfolio has potential to exceed EUR 200 million in peak annual sales.
- Orion has developed and launched in Europe a generic levodopa-carbidopa Parkinson's disease product. Other products with generic substances for Parkinson's disease are under development.
Orion is planning to initiate a Phase I clinical trial with ODM-212 in H2 2023. ODM-212 is a TEAD inhibitor, aimed for the treatment of solid tumours with YAP/TEAD activation.
Based on, among others, recent initiatives and recommendations1,2,3 by healthcare systems and health organisations to prefer dry-powder inhalers over metered-dose inhalers due to climatic reasons, Orion sees further growth potential to its Easyhaler® product portfolio. Orion estimates that Easyhaler® product portfolio has potential to exceed EUR 200 million in peak annual sales.
Orion's innovation entacapone remains one of the cornerstones of Parkinson's disease treatment and Orion remains an established company in the field of Parkinson's disease. Orion has developed a generic levodopa-carbidopa product for the treatment of Parkinson's disease and the product is in a launch phase in Europe. In addition, Orion is developing other combination products with generic substances for the treatment of Parkinson's disease. These new products will complement Orion's offering and strengthen the Company's position in Parkinson's disease market.
Orion's Capital Markets Day starts at 13:00 EEST and anyone can follow the event via a live webcast at https://orion.videosync.fi/cmd-25-5-23.
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
Tel. +358 10 426 2721
Reference
1https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf
2https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2022/07/B1728-delivering-a-net-zero-nhs-july-2022.pdf
3https://register.awmf.org/assets/guidelines/053_D_Ges_fuer_Allgemeinmedizin_und_Familienmedizin/053-059eng_S1_Climate-conscious-prescription-of-inhaled-medications_2022-09.pdf
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
